ChondroGene to develop clinical information database with Permanente

By Angela McDaniels

Seattle, Oct. 28 - ChondroGene Ltd. said it has entered into an agreement with the Division of Research of the Permanente Medical Group of Northern California to jointly develop a research database infrastructure that will be used for genomic research.

When developed, the genomic database will serve as a repository of clinical information generated by Permanente researchers for evaluating assays that use ChondroGene's Sentinel Principle, which is used to detect medical conditions in patients from blood samples.

ChondroGene said the principal objectives of the database are to standardize and achieve consistency in the format of data for future studies. This common format will also facilitate the testing of biospecimens at ChondroGene.

ChondroGene is a biotechnology company based in Toronto that develops functional genomics applications used to detect disease-specific biomarkers in blood samples.

The Permanente Medical Group of Northern California is one of eight physician groups that are part of Kaiser Permanente, a health care organization headquartered in Oakland, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.